Pfizer Draws Curtain On Anti-infective Research; Refocuses On Next-gen Vaccines
This article was originally published in PharmAsia News
The maker of some of the most well-known anti-infectives is now exiting the segment and will focus instead on prophylactic vaccines where it may face some surprises in combating deadly infections.
You may also be interested in...
Updates from the holiday season include a Phase III failure for Pfizer's MRSA vaccine, AbbVie's submission of upadacitinib for rheumatoid arthritis and several year-end US approvals and FDA actions.
Sens. Michael Bennet, D-Colo., and Orrin Hatch, R-Utah, signal Congressional revival of the Limited Population Antibacterial Development Program, offering antibiotics as the guinea pig for a potentially broader “limited-use” pathway.
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.